

Ziya Kirkali

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3793086/publications.pdf>

Version: 2024-02-01

231
papers

8,007
citations

81900

39
h-index

58581

82
g-index

241
all docs

241
docs citations

241
times ranked

7915
citing authors

#	ARTICLE	IF	CITATIONS
1	Experimental Pain and Auditory Sensitivity in Overactive Bladder Syndrome: A Symptoms of the Lower Urinary Tract Dysfunction Research Network (LURN) Study. <i>Journal of Urology</i> , 2022, 207, 161-171.	0.4	1
2	Poor clinical guideline adherence and inappropriate testing for incident lower urinary tract symptoms associated with benign prostatic hyperplasia. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 269-273.	3.9	13
3	Quality of life impact and recovery after ureteroscopy and stent insertion: insights from daily surveys in STENTS. <i>BMC Urology</i> , 2022, 22, 53.	1.4	5
4	Study to Enhance Understanding of Stent-Associated Symptoms: Rationale and Study Design. <i>Journal of Endourology</i> , 2021, 35, 761-768.	2.1	9
5	National Trends in Neuromodulation for Urinary Incontinence Among Insured Adult Women and Men, 2004-2013: The Urologic Diseases in America Project. <i>Urology</i> , 2021, 150, 86-91.	1.0	3
6	Prevention of Urinary Stones With Hydration (PUSH): Design and Rationale of a Clinical Trial. <i>American Journal of Kidney Diseases</i> , 2021, 77, 898-906.e1.	1.9	19
7	Analgesic and Opioid Use for Patients Discharged from the Emergency Department with Ureteral Stones. <i>Journal of Endourology</i> , 2021, 35, 1067-1071.	2.1	2
8	Resolution of Hydronephrosis and Pain to Predict Stone Passage for Patients with Acute Renal Colic. <i>Urology</i> , 2021, , .	1.0	2
9	Accuracy of Patient Reported Stone Passage for Patients With Acute Renal Colic Treated in the Emergency Department. <i>Urology</i> , 2020, 136, 70-74.	1.0	7
10	Longitudinal changes in symptom-based female and male LUTS clusters. <i>Neurourology and Urodynamics</i> , 2020, 39, 393-402.	1.5	6
11	Relationship of symptom severity and bother in individuals seeking care for lower urinary tract symptoms. <i>Neurourology and Urodynamics</i> , 2020, 39, 2161-2170.	1.5	4
12	Patient demographic and psychosocial characteristics associated with 30-day recall of self-reported lower urinary tract symptoms. <i>Neurourology and Urodynamics</i> , 2020, 39, 1939-1948.	1.5	5
13	Prevalence, subtypes, and correlates of nocturia in the symptoms of Lower Urinary Tract Dysfunction Research Network cohort. <i>Neurourology and Urodynamics</i> , 2020, 39, 1098-1107.	1.5	14
14	A New Brief Clinical Assessment of Lower Urinary Tract Symptoms for Women and Men: LURN SI-10. <i>Journal of Urology</i> , 2020, 203, 164-170.	0.4	21
15	Trends in Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia, 2004 to 2013: the Urologic Diseases in America Project. <i>Journal of Urology</i> , 2020, 203, 171-178.	0.4	30
16	National Trends in the Surgical Management of Urinary Incontinence among Insured Women, 2004 to 2013: The Urologic Diseases in America Project. <i>Journal of Urology</i> , 2020, 203, 365-371.	0.4	17
17	Are three-day voiding diaries feasible and reliable? Results from the Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN) cohort. <i>Neurourology and Urodynamics</i> , 2019, 38, 2185-2193.	1.5	33
18	A new outcome measure for LUTS: Symptoms of Lower Urinary Tract Dysfunction Research Network Symptom Index-29 (LURN SI-29) questionnaire. <i>Neurourology and Urodynamics</i> , 2019, 38, 1751-1759.	1.5	22

#	ARTICLE	IF	CITATIONS
19	Pediatric Urinary Stone Disease in the United States: The Urologic Diseases in America Project. <i>Urology</i> , 2019, 129, 180-187.	1.0	43
20	The Distribution of Post-Void Residual Volumes in People Seeking Care in the Symptoms of Lower Urinary Tract Dysfunction Network Observational Cohort Study With Comparison to Asymptomatic Populations. <i>Urology</i> , 2019, 130, 22-28.	1.0	5
21	A Novel Proteomics Approach to Identify Serum and Urinary Biomarkers and Pathways that Associate with Lower Urinary Tract Symptoms in Men and Women: Pilot Results of the Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN) Study. <i>Urology</i> , 2019, 129, 35-42.	1.0	6
22	Relationship Between Central Obesity, General Obesity, Overactive Bladder Syndrome and Urinary Incontinence Among Male and Female Patients Seeking Care for Their Lower Urinary Tract Symptoms. <i>Urology</i> , 2019, 123, 34-43.	1.0	42
23	The Comprehensive Assessment of Self-Reported Urinary Symptoms: A New Tool for Research on Subtypes of Patients with Lower Urinary Tract Symptoms. <i>Journal of Urology</i> , 2019, 201, 1177-1183.	0.4	15
24	Biomarkers Implicated in Lower Urinary Tract Symptoms: Systematic Review and Pathway Analyses. <i>Journal of Urology</i> , 2019, 202, 880-889.	0.4	27
25	Can 7 or 30-Day Recall Questions Capture Self-Reported Lower Urinary Tract Symptoms Accurately?. <i>Journal of Urology</i> , 2019, 202, 770-778.	0.4	15
26	Patient Characteristics Associated with More Bother from Lower Urinary Tract Symptoms. <i>Journal of Urology</i> , 2019, 202, 585-591.	0.4	15
27	Symptom Based Clustering of Men in the LURN Observational Cohort Study. <i>Journal of Urology</i> , 2019, 202, 1230-1239.	0.4	9
28	Strengthening Research in Benign Urology: Dispelling Myths that Impede Success. <i>Journal of Urology</i> , 2019, 202, 42-44.	0.4	0
29	Prevalence and Characteristics of Urinary Incontinence in a Treatment Seeking Male Prospective Cohort: Results from the LURN Study. <i>Journal of Urology</i> , 2018, 200, 397-404.	0.4	21
30	Bowel function, sexual function, and symptoms of pelvic organ prolapse in women with and without urinary incontinence. <i>Neurourology and Urodynamics</i> , 2018, 37, 2586-2596.	1.5	16
31	Baseline Lower Urinary Tract Symptoms in Patients Enrolled in LURN: A Prospective, Observational Cohort Study. <i>Journal of Urology</i> , 2018, 199, 1023-1031.	0.4	48
32	Research Needs to Understand Self-Management of Lower Urinary Tract Symptoms: Summary of NIDDK Workshop. <i>Journal of Urology</i> , 2018, 199, 1408-1410.	0.4	3
33	Reasons for Seeking Clinical Care for Lower Urinary Tract Symptoms: A Mixed Methods Study. <i>Journal of Urology</i> , 2018, 199, 528-535.	0.4	17
34	The LURN Research Network Neuroimaging and Sensory Testing (NIST) Study: Design, protocols, and operations. <i>Contemporary Clinical Trials</i> , 2018, 74, 76-87.	1.8	7
35	Mental Health, Sleep and Physical Function in Treatment Seeking Women with Urinary Incontinence. <i>Journal of Urology</i> , 2018, 200, 848-855.	0.4	36
36	Symptom Based Clustering of Women in the LURN Observational Cohort Study. <i>Journal of Urology</i> , 2018, 200, 1323-1331.	0.4	20

#	ARTICLE	IF	CITATIONS
37	NIH research opportunities for the prevention and treatment for chronic conditions. <i>Translational Behavioral Medicine</i> , 2018, 8, 509-514.	2.4	2
38	Effect of Tamsulosin on Passage of Symptomatic Ureteral Stones. <i>JAMA Internal Medicine</i> , 2018, 178, 1051.	5.1	65
39	Evidence of the Impact of Diet, Fluid Intake, Caffeine, Alcohol and Tobacco on Lower Urinary Tract Symptoms: A Systematic Review. <i>Journal of Urology</i> , 2017, 198, 1010-1020.	0.4	66
40	Design and challenges of a randomized clinical trial of medical expulsive therapy (tamsulosin) for urolithiasis in the emergency department. <i>Contemporary Clinical Trials</i> , 2017, 52, 91-94.	1.8	7
41	PNFLBA-04 RANDOMIZED CLINICAL TRIAL OF TREATMENT WITH TAMSULOSIN BEGUN IN THE EMERGENCY DEPARTMENT TO PROMOTE PASSAGE OF URINARY STONES. <i>Journal of Urology</i> , 2017, 197, .	0.4	8
42	Re: Top cited articles in urology from Turkey. <i>Turkish Journal of Urology</i> , 2017, 43, 227-227.	1.3	0
43	Advancing a Comprehensive Approach to the Study of Lower Urinary Tract Symptoms. <i>Journal of Urology</i> , 2016, 196, 1342-1349.	0.4	22
44	Symptoms of Lower Urinary Tract Dysfunction Research Network. <i>Journal of Urology</i> , 2016, 196, 146-152.	0.4	40
45	Urinary Stone Disease: Advancing Knowledge, Patient Care, and Population Health. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1305-1312.	4.5	106
46	EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 3 Years of Maintenance Bacillus Calmette-Guérin. <i>European Urology</i> , 2016, 69, 60-69.	1.9	445
47	Role of Transition Zone Index in the Prediction of Clinical Benign Prostatic Hyperplasia. <i>Journal of Urological Surgery</i> , 2016, 3, 114-118.	0.1	3
48	Do we need new patient reported measures to evaluate lower urinary tract dysfunction?. <i>Indian Journal of Urology</i> , 2016, 32, 91.	0.6	2
49	PD39-01 SEXUAL FUNCTION ASSOCIATED WITH LOWER URINARY TRACT SYMPTOMS IN MEN WITH BENIGN PROSTATIC HYPERPLASIA: MTOPS COHORT OF CROSS-SECTIONAL AND LONGITUDINAL DATA. <i>Journal of Urology</i> , 2015, 193, .	0.4	0
50	Urinary Stone Disease: Progress, Status, and Needs. <i>Urology</i> , 2015, 86, 651-653.	1.0	63
51	Quality of Acute Care for Patients With Urinary Stones in the United States. <i>Urology</i> , 2015, 86, 914-921.	1.0	12
52	Cross-Sectional and Longitudinal Associations of Sexual Function with Lower Urinary Tract Symptoms in Men with Benign Prostatic Hyperplasia. <i>Journal of Urology</i> , 2015, 193, 231-238.	0.4	18
53	Novel research approaches for interstitial cystitis/bladder pain syndrome: thinking beyond the bladder. <i>Translational Andrology and Urology</i> , 2015, 4, 524-33.	1.4	25
54	Association of metallothionein expression and clinical response to cisplatin based chemotherapy in testicular germ cell tumors. <i>Central European Journal of Urology</i> , 2015, 68, 45-50.	0.3	6

#	ARTICLE	IF	CITATIONS
55	The International Prostate Forum introduction and history. <i>Asian Journal of Andrology</i> , 2015, 17, 863.	1.6	1
56	The MAPP research network: a novel study of urologic chronic pelvic pain syndromes. <i>BMC Urology</i> , 2014, 14, 57.	1.4	123
57	Change in Sexual Function in Men with Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Associated with Long-Term Treatment with Doxazosin, Finasteride and Combined Therapy. <i>Journal of Urology</i> , 2014, 191, 1828-1834.	0.4	61
58	Active surveillance for small renal tumors: Have clinical concerns been addressed so far?. <i>International Journal of Urology</i> , 2013, 20, 356-361.	1.0	8
59	Long-Term Effects of Doxazosin, Finasteride and Combination Therapy on Quality of Life in Men with Benign Prostatic Hyperplasia. <i>Journal of Urology</i> , 2013, 190, 187-193.	0.4	25
60	Reply to JÃ©rÃ©me Verine's Letter to the Editor re: Rodolfo Montironi, Marina Scarpelli, Liang Cheng, et al. Immunoglobulin G4-related Disease in Genitourinary Organs: An Emerging Fibroinflammatory Entity Often Misdiagnosed Preoperatively as Cancer. <i>Eur Urol</i> . In press. http://dx.doi.org/10.1016/j.eururo.2012.11.056 . <i>European Urology</i> , 2013, 64, e53-e54.	1.9	0
61	Immunoglobulin G4-related Disease in Genitourinary Organs: An Emerging Fibroinflammatory Entity Often Misdiagnosed Preoperatively as Cancer. <i>European Urology</i> , 2013, 64, 865-872.	1.9	23
62	Can We Change Patient Behaviors to Improve Urological Health?. <i>Journal of Urology</i> , 2013, 190, 383-384.	0.4	0
63	Emergency department visits, use of imaging, and drugs for urolithiasis have increased in the United States. <i>Kidney International</i> , 2013, 83, 479-486.	5.2	170
64	Somatostatin receptor expression in prostate carcinoma: the urological pathologist's role in the era of personalised medicine. <i>Pathology</i> , 2013, 45, 93-96.	0.6	4
65	Genito-Urological Cancers in Elderly Patients. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2013, 13, 1391-1405.	1.7	6
66	Positive Surgical Margins After Nephron-Sparing Surgery. <i>European Urology</i> , 2012, 61, 757-763.	1.9	186
67	Unclassified renal cell carcinoma: a report of 56 cases. <i>BJU International</i> , 2012, 110, 786-793.	2.5	38
68	Lymphocytic vasculitis of the prostate transition zone. <i>BJU International</i> , 2012, 110, 1775-1780.	2.5	7
69	716 PHASE III STUDY OF INTERMITTENT MAB VS CONTINUOUS MAB. <i>Journal of Urology</i> , 2011, 185, .	0.4	3
70	Adverse events from targeted therapies in advanced renal cell carcinoma: the impact on long-term use. <i>BJU International</i> , 2011, 107, 1722-1732.	2.5	15
71	Inverted (Endophytic) Noninvasive Lesions and Neoplasms of the Urothelium: The Cinderella Group Has Yet to Be Fully Exploited. <i>European Urology</i> , 2011, 59, 225-230.	1.9	23
72	Reply to Kiril Trpkov, Asli Yilmaz Letter to the Editor re: Rodolfo Montironi, Liang Cheng, Antonio Lopez-Beltran, et al. Original Gleason System Versus 2005 ISUP Modified Gleason System: The Importance of Indicating Which System Is Used in the Patient's Pathology and Clinical Reports. <i>Eur Urol</i> 2010;58:369-73. <i>European Urology</i> , 2011, 59, e7-e8.	1.9	0

#	ARTICLE	IF	CITATIONS
73	Sequential Intravesical Chemoimmunotherapy with Mitomycin C and Bacillus Calmette-Guérin and with Bacillus Calmette-Guérin Alone in Patients with Carcinoma in Situ of the Urinary Bladder: Results of an EORTC Genito-Urinary Group Randomized Phase 2 Trial (30993). <i>European Urology</i> , 2011, 59, 438-446.	1.9	42
74	Toxicities of Targeted Therapy and Their Management in Kidney Cancer. <i>European Urology</i> , 2011, 59, 526-540.	1.9	119
75	Contemporary Management of Small Renal Masses. <i>European Urology</i> , 2011, 60, 501-515.	1.9	164
76	ICUD-EAU International Consultation on Kidney Cancer 2010: Treatment of Metastatic Disease. <i>European Urology</i> , 2011, 60, 684-690.	1.9	125
77	International Consultation on Urologic Diseases and the European Association of Urology International Consultation on Locally Advanced Renal Cell Carcinoma. <i>European Urology</i> , 2011, 60, 673-683.	1.9	25
78	Basic Research in Kidney Cancer. <i>European Urology</i> , 2011, 60, 622-633.	1.9	55
79	Renal Cell Carcinoma: A Changing Paradigm With a Need for Consensus. <i>European Urology</i> , 2011, 60, 613-614.	1.9	0
80	Histologic grading of urothelial papillary neoplasms: impact of combined grading (two-numbered) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Und Fur Klinische Medizin, 2011, 458, 659-664.	2.8	25
81	Management of advanced prostate cancer – new drugs. <i>Acta OncolŃgica</i> , 2011, 50, 137-140.	1.8	1
82	Somatostatin receptor subtypes in hormone-refractory (castration-resistant) prostatic carcinoma. <i>Asian Journal of Andrology</i> , 2011, 13, 242-247.	1.6	7
83	Reply to JosŃ I. LopŃz's Letter to the Editor re: Rodolfo Montironi, Liang Cheng, Antonio Lopez-Beltran, et al. Stage pT0 in Radical Prostatectomy with No Residual Carcinoma and with a Previous Positive Biopsy Conveys a Wrong Message to Clinicians and Patients: Why Is Cancer Not Present in the Radical Prostatectomy Specimen? <i>Eur Urol</i> 2009;56:272Ń4. <i>European Urology</i> , 2010, 57, e22-e23.	1.9	1
84	The Motion: Cryotherapy is an Efficient Alternative for Kidney Cancer. <i>European Urology</i> , 2010, 57, 168-170.	1.9	4
85	A Critical Analysis of the Actual Role of Minimally Invasive Surgery and Active Surveillance for Kidney Cancer. <i>European Urology</i> , 2010, 57, 223-232.	1.9	130
86	Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guérin, and Bacillus Calmette-Guérin plus Isoniazid in Patients with Intermediate- and High-Risk Stage Ta T1 Urothelial Carcinoma of the Bladder. <i>European Urology</i> , 2010, 57, 766-773. http://dx.doi.org/10.1016/j.eururo.2010.07.015 Letter to the Editor by Richard J. Sylvester, Maurizio A. Brausi, Wim J. Kirkels, et al. Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guérin, and Bacillus Calmette-Guérin plus Isoniazid in Patients with Intermediate- and High-Risk Stage Ta T1 Urothelial Carcinoma of the Bladder. <i>Eur Urol</i> 2010;57:766Ń73. http://dx.doi.org/10.1016/j.eururo.2010.07.015	1.9	347
87	Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guérin, and Bacillus Calmette-Guérin plus Isoniazid in Patients with Intermediate- and High-Risk Stage Ta T1 Urothelial Carcinoma of the Bladder. <i>Eur Urol</i> 2010;57:766Ń73. http://dx.doi.org/10.1016/j.eururo.2010.07.015	1.9	0
88	Editorial Comment on: Predicting Occult Multifocality of Renal Cell Carcinoma. <i>European Urology</i> , 2010, 58, 126.	1.9	2
89	Re: Matthias May, Sabine Brookman-Amisshah, Jan Roigas, et al. Prognostic Accuracy of Individual Uropathologists in Noninvasive Urinary Bladder Carcinoma: A Multicentre Study Comparing the 1973 and 2004 World Health Organisation Classifications. <i>Eur Urol</i> 2010;57:850Ń8. <i>European Urology</i> , 2010, 58, e7.	1.9	3
90	Prognostic and Therapeutic Impact of the Histopathologic Definition of Parenchymal Epithelial Renal Tumors. <i>European Urology</i> , 2010, 58, 655-668.	1.9	84

#	ARTICLE	IF	CITATIONS
91	Integrating Surgery with Targeted Therapies for Renal Cell Carcinoma: Current Evidence and Ongoing Trials. <i>European Urology</i> , 2010, 58, 819-828.	1.9	89
92	Genetic profiles in renal tumors. <i>International Journal of Urology</i> , 2010, 17, 6-19.	1.0	10
93	The Changing Face of Renal-Cell Carcinoma. <i>Journal of Endourology</i> , 2010, 24, 753-757.	2.1	2
94	1474 SEQUENTIAL CHEMO-IMMUNOTHERAPY WITH MITOMYCIN C (MMC) AND BACILLUS CALMETTE-GUERIN (BCG) VERSUS BCG ALONE IN PATIENTS WITH CARCINOMA IN SITU (CIS) OF THE URINARY BLADDER. RESULTS OF EORTC GU GROUP RANDOMIZED PHASE II STUDY 30993. <i>Journal of Urology</i> , 2010, 183, .	0.4	0
95	Ablative therapies in the treatment of small renal tumors: How far from standard of care?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010, 28, 251-259.	1.6	12
96	What is new in kidney cancer?. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 1753-1755.	2.4	0
97	Systemic therapy of kidney cancer: tyrosine kinase inhibitors, antiangiogenesis or IL-2?. <i>Future Oncology</i> , 2009, 5, 871-888.	2.4	6
98	Editorial Comment on: Prognostic Value of Renal Vein and Inferior Vena Cava Involvement in Renal Cell Carcinoma. <i>European Urology</i> , 2009, 55, 460.	1.9	2
99	Critical Evaluation of the Prostate from Cystoprostatectomies for Bladder Cancer: Insights from a Complete Sampling with the Whole Mount Technique. <i>European Urology</i> , 2009, 55, 1305-1309.	1.9	27
100	Intermittent Androgen Deprivation for Locally Advanced and Metastatic Prostate Cancer: Results from a Randomised Phase 3 Study of the South European Urooncological Group. <i>European Urology</i> , 2009, 55, 1269-1277.	1.9	213
101	Stage pT0 in Radical Prostatectomy with No Residual Carcinoma and with a Previous Positive Biopsy Conveys a Wrong Message to Clinicians and Patients: Why Is Cancer Not Present in the Radical Prostatectomy Specimen?. <i>European Urology</i> , 2009, 56, 272-274.	1.9	16
102	Joint Appraisal of the Radical Prostatectomy Specimen by the Urologist and the Uropathologist: Together, We Can Do It Better. <i>European Urology</i> , 2009, 56, 951-955.	1.9	23
103	2009 update on the classification of renal epithelial tumors in adults. <i>International Journal of Urology</i> , 2009, 16, 432-443.	1.0	207
104	Urothelial and incidental prostate carcinoma in prostates from cystoprostatectomies for bladder cancer: is there a relationship between urothelial and prostate cancer?. <i>BJU International</i> , 2009, 103, 1058-1063.	2.5	29
105	Neuroendocrine tumours of the urinary system and male genital organs: clinical significance. <i>BJU International</i> , 2009, 103, 1464-1470.	2.5	94
106	Secondary neoplasms of the urinary system and male genital organs. <i>BJU International</i> , 2009, 104, 770-776.	2.5	72
107	Prediction of Prostatic Involvement by Urothelial Carcinoma in Radical Cystoprostatectomy for Bladder Cancer. <i>Urology</i> , 2009, 74, 385-390.	1.0	22
108	Urologic oncology in southern Europe: Perceived problems and current plans. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009, 27, 121-122.	1.6	0

#	ARTICLE	IF	CITATIONS
109	Kidney cancer in the elderly. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009, 27, 673-676.	1.6	6
110	Multigene Methylation Analysis of Conventional Renal Cell Carcinoma. <i>Urologia Internationalis</i> , 2009, 83, 107-112.	1.3	27
111	Prostate Cancer: New Insights into Minimal and Localised Disease: Active Surveillance. <i>European Urology Supplements</i> , 2009, 8, 718-720.	0.1	1
112	Rare and unusual histological variants of prostatic carcinoma: clinical significance. <i>BJU International</i> , 2008, 102, 1369-1374.	2.5	56
113	Editorial Comment on: Preservation of Renal Function Following Partial or Radical Nephrectomy Using 24-Hour Creatinine Clearance. <i>European Urology</i> , 2008, 54, 151-152.	1.9	0
114	Editorial Comment on: Results of Endoluminal Occlusion of the Inferior Vena Cava During Radical Nephrectomy and Thrombectomy. <i>European Urology</i> , 2008, 54, 783-784.	1.9	1
115	Will We Be Able to "Cure" Metastatic Renal Cell Carcinoma Like We Cure Testicular Tumours?. <i>European Urology</i> , 2008, 54, 712-714.	1.9	3
116	Targeted therapies and biological modifiers in urologic tumors: pathobiology and clinical implications. <i>Seminars in Diagnostic Pathology</i> , 2008, 25, 232-244.	1.5	9
117	PROGNOSTIC FACTORS IN PATIENTS WITH INTERMEDIATE AND HIGH RISK STAGE Ta T1 PAPILLARY CARCINOMA OF THE BLADDER TREATED WITH MAINTENANCE EPIRUBICIN OR MAINTENANCE BACILLUS CALMETTE-GUERIN. RESULTS OF EORTC GU GROUP STUDY 30911. <i>Journal of Urology</i> , 2008, 179, 586-586.	0.4	1
118	Chairmen's Summary. <i>Scandinavian Journal of Urology and Nephrology</i> , 2008, 42, 7-11.	1.4	12
119	Open Partial Nephrectomy in the Management of Small Renal Masses. <i>Advances in Urology</i> , 2008, 2008, 1-7.	1.3	13
120	Advanced Tumors: Tumor Thrombus. , 2008, , 237-252.		2
121	Renal Cell Carcinoma: Overview. , 2008, , 263-280.		6
122	A Novel Resectoscope for Transurethral Resection of Bladder Tumors and the Prostate. <i>Journal of Urology</i> , 2007, 178, 2331-2336.	0.4	15
123	Editorial: Special Issue. Current Treatment of Localized Renal Cancer. <i>Scientific World Journal</i> , The, 2007, 7, 1046-1046.	2.1	0
124	Histologic Grading of Noninvasive Papillary Urothelial Neoplasms. <i>European Urology</i> , 2007, 51, 889-898.	1.9	131
125	What Does the Urologist Expect from the Pathologist (and What Can the Pathologists Give) in Reporting on Adult Kidney Tumour Specimens?. <i>European Urology</i> , 2007, 51, 1194-1201.	1.9	29
126	Re: Nephroureterectomy for Treating Upper Urinary Tract Transitional Cell Carcinoma. Time to Change the Treatment Paradigm?. <i>European Urology</i> , 2007, 51, 1141-1142.	1.9	2

#	ARTICLE	IF	CITATIONS
127	A Critical Analysis of Surgery for Kidney Cancer with Vena Cava Invasion. <i>European Urology</i> , 2007, 52, 658-662.	1.9	144
128	Reply to Apostolos P. Labanaris et al's Letter to the Editor re: Ziya Kirkali and Hein Van Poppel. A Critical Analysis of Surgery for Kidney Cancer with Vena Cava Invasion. <i>Eur Urol</i> 2007;52:658-662. <i>European Urology</i> , 2007, 52, 1801-1802.	1.9	0
129	1728: A Novel Resectoscope for Transurethral Resection of Bladder Tumors and the Prostate. <i>Journal of Urology</i> , 2007, 177, 575-575.	0.4	0
130	The motion: open partial nephrectomy is the standard of care for small resectable solid renal masses. <i>European Urology</i> , 2007, 51, 561-2; discussion 564.	1.9	5
131	Beyond Skeletal-Related Events. <i>European Urology Supplements</i> , 2006, 5, 553-555.	0.1	0
132	Superficial Urothelial Cancer in the Prostatic Urethra. <i>Scientific World Journal</i> , The, 2006, 6, 2603-2610.	2.1	9
133	Editorial: Superficial Bladder Cancer. <i>Scientific World Journal</i> , The, 2006, 6, 2646-2646.	2.1	0
134	Expression of Cathepsin D in Bladder Carcinoma: Correlation with Pathological Features and Serum Cystatin C Levels. <i>Tumori</i> , 2006, 92, 230-235.	1.1	16
135	Effects of finasteride on the vascular surface density, number of microvessels and vascular endothelial growth factor expression of the rat prostate. <i>International Urology and Nephrology</i> , 2006, 38, 275-280.	1.4	15
136	The Future of Oncological Urology in Europe: Are we Prepared?. <i>European Urology</i> , 2006, 49, 11-12.	1.9	3
137	2004 WHO Classification of the Renal Tumors of the Adults. <i>European Urology</i> , 2006, 49, 798-805.	1.9	728
138	Expression of COX-2 in Normal and Pyelonephritic Kidney, Renal Intraepithelial Neoplasia, and Renal Cell Carcinoma. <i>European Urology</i> , 2006, 50, 92-97.	1.9	23
139	Association of Mast Cells with Microvessel Density in Renal Cell Carcinomas. <i>European Urology</i> , 2006, 50, 530-534.	1.9	70
140	Reply to Dr Zdemir's Letter to the Editor re: Burcin Tuna, Kutsal Yorukoglu, Mehtat Unlu, M. Ugur Mungan and Ziya Kirkali, Association of Mast Cells with Microvessel Density in Renal Cell Carcinomas. <i>Eur Urol</i> . 2006;50:530-534. <i>European Urology</i> , 2006, 50, 621-622.	1.9	0
141	Puigvert: A Man with a Vision—Nephron-Sparing Surgery 30 Years Ago in Europe. <i>European Urology</i> , 2006, 50, 175-185.	1.9	0
142	Editorial: Superficial Bladder Cancer. <i>TSW Urology</i> , 2006, 1, 44-44.	0.1	0
143	Current management of renal cell carcinoma and targeted therapy. <i>Urology Journal</i> , 2006, 3, 1-14.	0.4	28
144	1,25 Dihydroxyvitamin D Receptor Expression in Superficial Transitional Cell Carcinoma of the Bladder: A Possible Prognostic Factor?. <i>European Urology</i> , 2005, 47, 52-57.	1.9	23

#	ARTICLE	IF	CITATIONS
145	Risk Factors for Mucosal Prostatic Urethral Involvement in Superficial Transitional Cell Carcinoma of the Bladder. <i>European Urology</i> , 2005, 48, 760-763.	1.9	52
146	Echo Contrast-Enhanced Power Doppler Ultrasonography for Assessment of Angiogenesis in Renal Cell Carcinoma. <i>Journal of Ultrasound in Medicine</i> , 2005, 24, 747-753.	1.7	18
147	Can mycoplasma-mediated oncogenesis be responsible for formation of conventional renal cell carcinoma?. <i>Urology</i> , 2005, 65, 411-414.	1.0	31
148	Bladder cancer: Epidemiology, staging and grading, and diagnosis. <i>Urology</i> , 2005, 66, 4-34.	1.0	825
149	Handling and Pathology Reporting of Renal Tumor Specimens. <i>European Urology</i> , 2004, 45, 437-443.	1.9	41
150	Handling and Pathology Reporting of Adrenal Gland Specimens. <i>European Urology</i> , 2004, 45, 722-729.	1.9	7
151	Conservative Management of Mucosal Prostatic Urethral Involvement in Patients with Superficial Transitional Cell Carcinoma of the Bladder. <i>European Urology</i> , 2004, 45, 465-470.	1.9	18
152	Gemcitabine-induced vasculitis in advanced transitional cell carcinoma of the bladder. <i>Journal of Cancer Research and Clinical Oncology</i> , 2004, 130, 122-125.	2.5	22
153	Urothelial carcinoma of the bladder with trophoblastic differentiation: A case report. <i>International Urology and Nephrology</i> , 2004, 36, 529-531.	1.4	6
154	Premalignant lesions of the kidney share the same genetics changes as conventional renal cell carcinoma. <i>World Journal of Urology</i> , 2004, 22, 120-3.	2.2	11
155	Significance of heat shock protein-27 expression in patients with renal cell carcinoma. <i>Urology</i> , 2004, 64, 474-478.	1.0	32
156	Significance of COX-2 expression in human renal cell carcinoma. <i>Urology</i> , 2004, 64, 1116-1120.	1.0	43
157	Developments in Organ Preserving Treatments for Renal Cell Cancer: Open Surgery. <i>European Urology Supplements</i> , 2004, 3, 9-13.	0.1	4
158	Expression of p53 and mdm2 and Their Significance in Recurrence of Superficial Bladder Cancer. <i>Pathology Research and Practice</i> , 2003, 199, 323-328.	2.3	22
159	Reproducibility of the 1998 World Health Organization/International Society of Urologic Pathology classification of papillary urothelial neoplasms of the urinary bladder. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2003, 443, 734-740.	2.8	60
160	Transitional cell carcinoma of the ureter and renal pelvis. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 47, 155-169.	4.4	193
161	RE: Etiology of Spontaneous Perirenal Hemorrhage: A Meta-Analysis. <i>Journal of Urology</i> , 2003, 170, 548-548.	0.4	0
162	Primary renal lymphoma of mucosa-associated lymphoid tissue. <i>Urology</i> , 2003, 61, 463.	1.0	35

#	ARTICLE	IF	CITATIONS
163	Clinical Aspects of Renal Cell Carcinoma. EAU Update Series, 2003, 1, 189-196.	0.5	22
164	Intermittent Androgen Deprivation for Locally Advanced Prostate Cancer. Oncology, 2003, 65, 24-28.	1.9	11
165	Renal cell carcinoma: new prognostic factors?. Current Opinion in Urology, 2003, 13, 433-438.	1.8	25
166	Bone Mineral Density and Biochemical Markers of Bone in Patients With Idiopathic Hypercalciuria. , 2003, 13, 417-421.		1
167	RE: THE PATIENT WITH CHRONIC EPIDIDYMITIS: CHARACTERIZATION OF AN ENIGMATIC SYNDROME. Journal of Urology, 2002, 168, 2132-2133.	0.4	3
168	Prognostic Significance of Estrogen Receptor Expression in Superficial Transitional Cell Carcinoma of the Urinary Bladder. European Urology, 2002, 41, 342-345.	1.9	33
169	Prognostic significance of nuclear morphometry in renal cell carcinoma. BJU International, 2002, 90, 20-25.	2.5	19
170	A Prospective Survey of Surgical Approaches in Clinically Localized Renal Cell Carcinoma--A Preliminary Attempt at Surgical Quality Control. UroOncology, 2002, 2, 169-174.	0.1	3
171	METALLOTHIONEIN EXPRESSION IN RENAL CELL CARCINOMA: SUBCELLULAR LOCALIZATION AND PROGNOSTIC SIGNIFICANCE. Journal of Urology, 2001, 165, 1710-1713.	0.4	28
172	Quality control of radical prostatectomy. European Journal of Cancer, 2001, 37, 884-891.	2.8	26
173	Does angiogenesis predict recurrence in superficial transitional cell carcinoma of the bladder?. Urology, 2001, 57, 895-899.	1.0	22
174	Expression of PS2 Protein and Its Relation with the Ki–67 Proliferative Indices and Tumor Recurrence in Superficial Bladder Carcinomas. European Urology, 2001, 40, 163-168.	1.9	3
175	Significance of Tissue Laminin P₁ Elastase and Fibronectin Levels in Transitional Cell Carcinoma of the Bladder. European Urology, 2001, 39, 292-299.	1.9	17
176	Testis sparing surgery for the treatment of a sequential bilateral testicular germ cell tumor. International Journal of Urology, 2001, 8, 710-712.	1.0	14
177	Proliferative activity, angiogenesis and nuclear morphometry in renal cell carcinoma. International Journal of Urology, 2001, 8, 697-703.	1.0	18
178	Recent advances in kidney cancer and metastatic disease. BJU International, 2001, 88, 818-824.	2.5	54
179	Ondansetron versus diclofenac sodium in the treatment of acute ureteral colic: a double blind controlled trial. International Urology and Nephrology, 2001, 33, 315-319.	1.4	8
180	Vertebral Fracture Associated with Shockwave Lithotripsy in a Patient with Granulomatous Spondylitis. Journal of Endourology, 2001, 15, 687-689.	2.1	1

#	ARTICLE	IF	CITATIONS
181	METALLOTHIONEIN EXPRESSION IN RENAL CELL CARCINOMA: Journal of Urology, 2001, , 1710-1713.	0.4	1
182	Ganglion cells in the human prostate. Prostate Cancer and Prostatic Diseases, 2000, 3, 34-36.	3.9	4
183	Precancerous Lesions in the Kidney. Scandinavian Journal of Urology and Nephrology, 2000, 34, 136-165.	1.4	20
184	Precancerous Lesions in the Kidney. Scandinavian Journal of Urology and Nephrology, 2000, 34, 136-165.	1.4	20
185	Comparison of Microvascularization in Diagnostic Needle Biopsies and Radical Prostatectomies in Prostate Carcinoma. European Urology, 1999, 35, 109-112.	1.9	9
186	PHARMACOLOGICAL ANALYSIS OF 5-HYDROXYTRYPTAMINE EFFECTS ON HUMAN ISOLATED URETER. Pharmacological Research, 1999, 39, 487-491.	7.1	8
187	Tubular dysplasia and carcinoma in situ: precursors of renal cell carcinoma. Urology, 1999, 53, 684-689.	1.0	21
188	Prognostic significance of angiogenesis and immunoreactivity of cathepsin d and type IV collagen in high-grade stage T1 primary bladder cancer. Urology, 1999, 54, 50-55.	1.0	34
189	RE: URINARY TRACT CANCER AND HEREDITARY NONPOLYPOSIS COLORECTAL CANCER. Journal of Urology, 1999, 161, 926-926.	0.4	0
190	RE: RECURRENT BILATERAL AMIODARONE INDUCED EPIDIDYMITIS. Journal of Urology, 1999, 162, 808-809.	0.4	9
191	Serum Ferritin as a Clinical Marker for Renal Cell Carcinoma: Influence of Tumor Size and Volume. Urologia Internationalis, 1999, 62, 21-25.	1.3	42
192	Renal Cell Carcinoma with Gallbladder Metastasis. International Journal of Urology, 1998, 5, 288-290.	1.0	17
193	Investigation of p53, c-erbB-2, PCNA immunoreactivity, DNA content, AgNOR and apoptosis in bladder carcinoma as prognostic parameters. Cancer Letters, 1998, 126, 143-148.	7.2	15
194	RENAL BOTRYOMYCOSIS MIMICKING RENAL CELL CARCINOMA. Journal of Urology, 1998, 159, 2076-2076.	0.4	8
195	Renal Effects of Carbon Dioxide Insufflation in Rabbit Pneumoretroperitoneum Model. Journal of Endourology, 1998, 12, 367-370.	2.1	28
196	Volume-weighted mean nuclear volume in renal cell carcinoma. Urology, 1998, 52, 44-47.	1.0	14
197	Locally Recurrent Paratesticular Rhabdomyosarcoma Treated with Surgery and Radiotherapy. Urologia Internationalis, 1998, 60, 264-265.	1.3	1
198	Is Magnetic Resonance Imaging Necessary in the Staging of Prostate Cancer?. Urologia Internationalis, 1998, 61, 227-231.	1.3	18

#	ARTICLE	IF	CITATIONS
199	RENAL BOTRYOMYCOSIS MIMICKING RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 1998, 159, 2076.	0.4	2
200	Contractility Changes of the Deep Dorsal Penile Vein Due to Serotonin. <i>Journal of Urology</i> , 1997, 158, 234-237.	0.4	10
201	Testicular Microlithiasis Associated with Teratocarcinoma and Intratubular Germ Cell Neoplasia: A Case Report. <i>International Journal of Urology</i> , 1997, 4, 530-532.	1.0	4
202	Bellini duct (collecting duct) carcinoma of the kidney. <i>Urology</i> , 1996, 47, 921-923.	1.0	22
203	Significance of serum lam1nin P1 values in patients with transitional cell carcinoma of the bladder. <i>Urology</i> , 1996, 48, 496-500.	1.0	11
204	^{99m} Tc-MIBI scintigraphy in metastatic renal cell carcinoma: clinical validation of the relationship between ^{99m} Tc-MIBI uptake and P-170 protein expression in tumour tissue. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1996, 23, 976-979.	2.1	21
205	Cisplatin and Etoposide Chemotherapy in the Treatment of Adult Wilms's Tumor. <i>Urologia Internationalis</i> , 1996, 57, 108-109.	1.3	0
206	Effect of Extracorporeal Shockwave Lithotripsy on Plasma and Urine Endothelin Concentrations. <i>Journal of Endourology</i> , 1996, 10, 325-327.	2.1	3
207	Effectiveness of Extracorporeal Shockwave Lithotripsy in the Management of Stone-Bearing Horseshoe Kidneys. <i>Journal of Endourology</i> , 1996, 10, 13-15.	2.1	50
208	Influence of Serotonin on the Human Ureter: An in vitro Pharmacological Study. <i>Urologia Internationalis</i> , 1995, 55, 202-204.	1.3	10
209	Ferritin: A Tumor Marker Expressed by Renal Cell Carcinoma. <i>European Urology</i> , 1995, 28, 131-134.	1.9	31
210	Prostatic carcinoma presenting with painless parotid mass. <i>Urology</i> , 1995, 46, 406-407.	1.0	12
211	The Effect of Extracorporeal Electromagnetic Shock Waves on the Morphology and Contractility of Rabbit Ureter. <i>Journal of Urology</i> , 1995, 154, 1939-1943.	0.4	23
212	Primary signet ring cell carcinoma of the bladder. <i>British Journal of Urology</i> , 1994, 73, 210-211.	0.1	5
213	Does Respiratory Gating Improve Extracorporeal Shockwave Lithotripsy Results?. <i>Journal of Endourology</i> , 1994, 8, 329-330.	2.1	3
214	Are Obstructing Ureteral Stones More Difficult to Treat with Extracorporeal Electromagnetic Shock Wave Lithotripsy?*. <i>Journal of Endourology</i> , 1993, 7, 277-279.	2.1	20
215	Place of Double-J Stents in Extracorporeal Shock Wave Lithotripsy. <i>European Urology</i> , 1993, 23, 460-462.	1.9	31
216	Extracorporeal Electromagnetic Shock Wave Lithotripsy of Ureteric Stones in Situ. <i>Journal of Endourology</i> , 1992, 6, 411-412.	2.1	2

#	ARTICLE	IF	CITATIONS
217	Cysts of the Prostate, Seminal Vesicles and Diverticulum of the Ejaculatory Ducts. <i>European Urology</i> , 1991, 20, 77-80.	1.9	17
218	Urological Aspects of Behcet's Disease. <i>British Journal of Urology</i> , 1991, 67, 638-639.	0.1	50
219	HLA Antigens and Transitional Cell Carcinoma of the Bladder. <i>Urologia Internationalis</i> , 1990, 45, 75-77.	1.3	8
220	Tunica Vaginalis: an Aid in Hypospadias Surgery. <i>British Journal of Urology</i> , 1990, 65, 530-532.	0.1	37
221	Silent Testicular Metastasis from Carcinoma of the Prostate. <i>British Journal of Urology</i> , 1990, 66, 205-207.	0.1	27
222	Epidemiological Case-Control Study on the Etiology of Bladder Cancer in Turkey. <i>European Urology</i> , 1990, 17, 23-26.	1.9	27
223	Androgen Receptors - A Method to Measure Functional Behaviour in Human Prostatic Cancer. <i>European Urology</i> , 1990, 17, 66-68.	1.9	1
224	Urothelial Tumours of the Upper Urinary Tract. <i>British Journal of Urology</i> , 1989, 64, 18-24.	0.1	16
225	Amiodarone-Induced Sterile Epididymitis. <i>Urologia Internationalis</i> , 1988, 43, 372-373.	1.3	14
226	Blood Groups and Transitional Cell Carcinoma of the Upper Urinary Tract. <i>European Urology</i> , 1988, 14, 22-23.	1.9	2
227	Unusual Metastases of Renal Cell Carcinoma. <i>Urologia Internationalis</i> , 1987, 42, 316-317.	1.3	14
228	Androgen receptors in TCC. <i>Urology</i> , 1987, 29, 674.	1.0	0
229	Ureteric perforation after ureteroscopy. <i>Urology</i> , 1987, 30, 595.	1.0	0
230	The Role of Delay in Stage-III Testicular Tumors. <i>European Urology</i> , 1986, 12, 151-153.	1.9	6
231	Experience with Treatment of Nonseminomatous Germ Cell Tumors of Testis in Turkey. , 1985, , 263-268.		0